Zealand Pharma A/S (ZEAL)’s Financial Results Comparing With BioXcel Therapeutics Inc. (NASDAQ:BTAI)

Zealand Pharma A/S (NASDAQ:ZEAL) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) compete with each other in the Biotechnology sector. We will analyze and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zealand Pharma A/S N/A 0.00 N/A 3.00 5.18
BioXcel Therapeutics Inc. N/A 0.00 19.27M -1.04 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Zealand Pharma A/S and BioXcel Therapeutics Inc.

Profitability

Table 2 provides Zealand Pharma A/S and BioXcel Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zealand Pharma A/S 0.00% 0% 0%
BioXcel Therapeutics Inc. 0.00% -40.1% -37.6%

Insider and Institutional Ownership

Institutional investors owned 9.28% of Zealand Pharma A/S shares and 20.6% of BioXcel Therapeutics Inc. shares. Insiders Competitively, owned 1.1% of BioXcel Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zealand Pharma A/S 6.55% 7.93% 34.59% 9.24% -2.23% 33.89%
BioXcel Therapeutics Inc. 8.12% 66.42% 85.45% -0.45% 0% 131.09%

For the past year Zealand Pharma A/S has weaker performance than BioXcel Therapeutics Inc.

Summary

Zealand Pharma A/S beats BioXcel Therapeutics Inc. on 5 of the 7 factors.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.